DMYD B Stock Overview
Develops precision medicine therapies for the treatment of autoimmune diabetes.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Diamyd Medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 18.62 |
| 52 Week High | SEK 25.00 |
| 52 Week Low | SEK 6.41 |
| Beta | 2.09 |
| 11 Month Change | 24.47% |
| 3 Month Change | 66.85% |
| 1 Year Change | 99.14% |
| 33 Year Change | -37.64% |
| 5 Year Change | 115.51% |
| Change since IPO | 315.63% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Diamyd Medical's (STO:DMYD B) Cash Burn Rate
Feb 02
We Think Diamyd Medical (STO:DMYD B) Needs To Drive Business Growth Carefully
Sep 22What You Need To Know About Diamyd Medical AB (publ)'s (STO:DMYD B) Investor Composition
Jan 22Here's Why Diamyd Medical's (STO:DMYD B) Statutory Earnings Are Arguably Too Conservative
Nov 30Shareholder Returns
| DMYD B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 3.3% | -6.1% | -0.6% |
| 1Y | 99.1% | 21.0% | 17.0% |
Return vs Industry: DMYD B exceeded the Swedish Biotechs industry which returned 20.5% over the past year.
Return vs Market: DMYD B exceeded the Swedish Market which returned 18.4% over the past year.
Price Volatility
| DMYD B volatility | |
|---|---|
| DMYD B Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: DMYD B's share price has been volatile over the past 3 months.
Volatility Over Time: DMYD B's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 25 | Ulf Hannelius | www.diamyd.com |
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes.
Diamyd Medical AB (publ) Fundamentals Summary
| DMYD B fundamental statistics | |
|---|---|
| Market cap | SEK 1.86b |
| Earnings (TTM) | -SEK 139.62m |
| Revenue (TTM) | SEK 185.00k |
Over9,999x
P/S Ratio-13.3x
P/E RatioIs DMYD B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMYD B income statement (TTM) | |
|---|---|
| Revenue | SEK 185.00k |
| Cost of Revenue | SEK 3.90m |
| Gross Profit | -SEK 3.72m |
| Other Expenses | SEK 135.91m |
| Earnings | -SEK 139.62m |
Last Reported Earnings
May 31, 2024
Next Earnings Date
Oct 09, 2024
| Earnings per share (EPS) | -1.40 |
| Gross Margin | -2,009.19% |
| Net Profit Margin | -75,471.35% |
| Debt/Equity Ratio | 0% |
How did DMYD B perform over the long term?
See historical performance and comparison